Generation Bio

Generation Bio P/FCF

Delisted

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Generation Bio (GBIO) as of Nov 10, 2026 is -0.40. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.60 — a change of -33.88% (higher).

P/FCF

-0.40

YoY

-33.88%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Generation Bio is 2024 -0.40 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Generation Bio was 2023 -0.60 . It decreases by -33.88% higher compared to the previous year.

The Generation Bio P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-1.16 USD
Jan 1, 2019
-0.60 USD
Jan 1, 2020
-0.48 USD
Jan 1, 2021
-0.37 USD
Jan 1, 2022
-0.32 USD
Jan 1, 2023
-0.60 USD
Jan 1, 2024
-0.40 USD
The Generation Bio P/FCF history
YEARP/FCFYoY
-0.40-33.88%
-0.60+84.98%
-0.32-12.11%
-0.37-22.62%
-0.48-20.26%
-0.60-48.39%
-1.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Generation Bio is -0.40 in 2024.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Generation Bio changed from -0.60 to -0.40, representing a -33.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Generation Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Generation Bio

All Key Metrics — Generation Bio